JNJ Factor-Based Stock Analysis

Validea's guru fundamental report, utilizing Warren Buffett's Patient Investor model, rates Johnson & Johnson (JNJ) at 72%, placing it below the 80% threshold typically indicating investment interest. While JNJ, a large-cap growth stock in the Biotechnology & Drugs sector, passes most fundamental criteria such as earnings predictability, debt service, and free cash flow, it notably fails the model's tests for "use of retained earnings" and "expected return," suggesting it does not fully meet the strategy's preference for long-term, predictable profitability at reasonable valuations.

Analysis

Johnson & Johnson (JNJ) receives a 72% rating from Validea's Patient Investor model, a framework based on Warren Buffett's investment strategy. This score falls below the 80% threshold that the model uses to indicate notable investment interest. The analysis reveals a company with strong underlying fundamentals, passing critical tests for earnings predictability, debt service, return on equity, return on total capital, free cash flow generation, and share repurchases. However, these strengths are offset by significant shortcomings, as JNJ fails the model's criteria for 'use of retained earnings' and 'expected return'. This mixed assessment suggests that while JNJ is a high-quality, stable enterprise, its current valuation and capital allocation efficiency do not meet the stringent return expectations required by this particular value-focused strategy.

Key Decisions for Investors

• Value-oriented investors should note that the failure on the 'expected return' metric suggests the stock may not offer a sufficient margin of safety at its current valuation according to this specific model.
• For investors holding the stock for its quality characteristics, the 'PASS' ratings on fundamentals like earnings predictability and debt service are supportive, but the 'FAIL' on 'use of retained earnings' warrants closer scrutiny of the company's capital allocation decisions.
• Traders and potential new investors should consider this a neutral signal, indicating that while the company is fundamentally sound, its prospects for outsized returns may be limited, justifying a hold or further due diligence on valuation.